Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

6.190
+0.0100.16%
Volume:3.81M
Turnover:24.03M
Market Cap:9.14B
PE:-86.61
High:6.430
Open:6.220
Low:6.160
Close:6.180
52wk High:13.150
52wk Low:2.030
Shares:1.48B
HK Float Shares:1.48B
Volume Ratio:0.80
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.071
ROE:-96.36%
ROA:-16.93%
PB:25.56
PE(LYR):-86.61
PS:39.77

Loading ...

CStone (HKEX: 2616) Gains UK MHRA Approval for Sugemalimab in Stage III NSCLC

Bulletin Express
·
3 hours ago

CStone Pharma-B's PD-L1 Antibody Sugemalimab Gains UK Approval for Advanced Lung Cancer

Stock News
·
4 hours ago

CStone Pharmaceuticals - Sugemalimab Receives UK Mhra Approval for Stage Iii Nsclc

THOMSON REUTERS
·
4 hours ago

UK MHRA approves CStone’s sugemalimab for unresectable stage III NSCLC

Reuters
·
4 hours ago

CSTONE PHARMA-B Receives FDA Clearance for Phase II Trial of CS2009

Stock News
·
Feb 20

CStone Pharmaceuticals (HKEX: 2616) Announces U.S. FDA IND Clearance for Phase II Trial of CS2009 Trispecific Antibody

Bulletin Express
·
Feb 16

CStone Pharmaceuticals' CS2009 Tri-Specific Antibody Phase II Trial Receives FDA Clearance

Stock News
·
Feb 16

CStone Pharmaceuticals Receives FDA Clearance for Phase II Trial of CS2009

Reuters
·
Feb 16

CStone Pharmaceuticals - FDA Clears Ind Application for Cs2009 Phase Ii Trial

THOMSON REUTERS
·
Feb 16

CStone Pharmaceuticals (2616) Updates Joint Company Secretary Qualification and Announces Personnel Changes

Bulletin Express
·
Feb 06

CStone Pharmaceuticals-B Receives Exchange Approval for Company Secretary Qualification

Stock News
·
Feb 06

CStone Pharmaceuticals Appoints Weicong Ni as Sole Company Secretary

Reuters
·
Feb 06

BRIEF-Cstone Pharmaceuticals's CEO Buys Aggregate Of 976,000 Shares From Nov 2025 To Jan 2026

Reuters
·
Jan 27

CSTONE PHARMA-B (02616) CEO & Executive Director Dr. Yang Jianxin Purchases Additional 976,000 Shares, Cumulative Holdings Reach 12.477 Million Shares

Stock News
·
Jan 27

CStone Pharmaceuticals - CEO Buys Aggregate of 976,000 Shares From Nov 2025 to Jan 2026

THOMSON REUTERS
·
Jan 27

CStone Pharmaceuticals (SEHK:2616) Valuation After New Equity Awards And Board Changes

Simply Wall St.
·
Jan 26

CStone Pharmaceuticals (2616) Announces Grant of 15.72 Million Share Options and 8.06 Million RSUs

Bulletin Express
·
Jan 23

CSTONE PHARMA-B (02616) Grants 15.7155 Million Share Options and 8.055 Million Restricted Share Units

Stock News
·
Jan 23

CSTONE PHARMA-B (02616): Yan Jiaxun Appointed as Independent Non-Executive Director

Stock News
·
Jan 21

CStone Pharmaceuticals Files Director List with HKEX

Reuters
·
Jan 21